Article
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2025
Ricciuti B, Scalera S, Wang X, Elkrief A, Tagliamento M, Gariazzo E, Paoloni F, Miller P G, Pecci F, Di Federico A, Santo V, Alessi J V, Aldea M, Garbo E, Lamberti G, Zrafi W, Micol J B, Sholl L M, Nishino M, Cappuzzo F, Calonaci N, Caravagna G, Ferrara R, Besse B, Schoenfeld A, Maugeri-Sacca M, Awad M M
Abstract excerpt
BACKGROUND: Despite significant improvements in overall survival with programmed cell death protein (ligand) 1 [PD-(L)1] inhibition, most patients with metastatic non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibition (ICI). Growing evidence suggests the importance of genomic alterations in modulating anticancer immune response and predicting ICI efficacy. However, the genomic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.